New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

CytomX Therapeutics Inc.

Contributing Author

Recent Articles by CytomX Therapeutics Inc.

Jan-08	CytomX Therapeutics Announces Business Update and Company Milestones for 2026 CTMX GlobeNewswire
Nov-25	CytomX Therapeutics to Present at Upcoming December Investor Conferences CTMX GlobeNewswire
Nov-13	CytomX Therapeutics to Present at the Jefferies London Healthcare Conference CTMX GlobeNewswire
Nov-06	CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update CTMX GlobeNewswire
Nov-04	CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting CTMX GlobeNewswire
Oct-30	CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025 CTMX GlobeNewswire
Oct-20	CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer CTMX GlobeNewswire
Aug-28	CytomX Therapeutics to Present at Upcoming September Investor Conferences CTMX GlobeNewswire
Aug-13	CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study CTMX GlobeNewswire
Aug-07	CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update CTMX GlobeNewswire
Jul-31	CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025 CTMX GlobeNewswire
May-29	CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference CTMX GlobeNewswire
May-19	CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA (pembrolizumab) in Patients with Metastatic Melanoma CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock CTMX GlobeNewswire
May-12	CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC) CTMX GlobeNewswire
May-12	CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update CTMX GlobeNewswire
May-05	CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025 CTMX GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.